Altre lingue RespireRx Pharmaceuticals Inc.

Azioni

RSPI

US7612273059

Mercato chiuso - OTC Markets Altri mercati azionari 21:55:31 03/05/2024			Variaz. 5gg	Var. 1 gen.
0,0009 ^USD	-18,18%		0,00%	0,00%

20/03	RespireRx Pharmaceuticals Inc. riferisce la pubblicazione dei risultati della ricerca preclinica che dimostrano la capacità di CX1739, la sua AMPAkine clinica di punta, di migliorare la funzione vescicale dopo la lesione del midollo spinale	CI
13/02	RespireRx Pharmaceuticals Inc. riferisce di aver ottenuto un sollievo dal dolore in fase preclinica per il suo leader non oppioide GABAkine	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding	10/04
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	20/03
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	20/03
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine	13/02
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for Their Non-Opioid Lead GABAkine	13/02
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors	22/01
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dariusz Naziek to its Board of Directors	22/01
RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient	04/01
Respirerx Pharmaceuticals Inc. Announces the Publication of A Case Report in Which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient	04/01
RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development	11/12
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	17/11
Today's Top OTC Stocks Watchlist (SWISF, EPAZ, ABQQ, RSPI)	13/10/23
RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services	12/10/23
RespireRx Pharmaceuticals : SETTLEMENT AND EXCHANGE AGREEMENT - Form 8-K	02/10/23
Attention Deficit Hyperactivity Disorder Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	26/09/23
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/08/23
CapitalGainsReport: Sub Penny Stocks Set To Soar: EPAZ, RSPI, TPTW, HGEN	10/08/23
RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company	09/08/23
RespireRx Pharmaceuticals : Cortex Pharmaceuticals, Inc. 2014 Equity, Equity-Linked and Equity Derivative Plan - Form 8-K	13/06/23
RESPIRERX PHARMACEUTICALS INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	13/06/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue RespireRx Pharmaceuticals Inc.

Azioni

RSPI

US7612273059

Altre lingue

Filtri